Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
FiercePharma14h
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
Bristol Myers expects to deliver additional ~$2B in cost savings by 2027-end
Squibb is expanding its existing strategic productivity initiative to include approximately $2B in additional annualized ...
devdiscourse6h
Health Sector Shake-Ups: From Bristol Myers' Forecasts to Global Aid Impacts
Recent health news includes Bristol Myers' projected revenue dip due to generic competition and cost cuts, Trump's tariffs ...
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...
BioPharma Dive9h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...